CASI Pharmaceuticals (CASIF) Revenue (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Revenue came in at $7.2 million in Q4 2025, down 45.93% YoY from $13.4 million in Q4 2024, and up 134.86% on a QoQ basis from $3.1 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Revenue (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of Revenue data on file, last reported at $7.2 million in Q4 2025.
- Quarterly Revenue fell 45.93% year-over-year to $7.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.7 million (down 27.42% YoY) and the FY2025 annual result came in at $20.7 million, down 27.42% from the prior year.
- Revenue improved to $7.2 million in Q4 2025, from $3.1 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $13.4 million in Q4 2024 to a low of $3.1 million in Q3 2025.
- A 4-year average of $7.6 million and a median of $8.1 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2024 — Revenue surged 94.3% — and 2025, when it slumped 60.54%.
- Tracing CASIF's Revenue over 4 years: stood at $10.3 million in 2022, then plunged by 33.0% to $6.9 million in 2023, then surged by 94.3% to $13.4 million in 2024, then plunged by 45.93% to $7.2 million in 2025.
- The last three Revenue figures came in at $7.2 million (Q4 2025), $3.1 million (Q3 2025), and $4.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 674.14 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.22 Mn |
| Sep 30, 2025 | 3.08 Mn |
| Jun 30, 2025 | 4.18 Mn |
| Mar 31, 2025 | 6.24 Mn |
| Dec 31, 2024 | 13.36 Mn |
| Sep 30, 2024 | 7.79 Mn |
| Jun 30, 2024 | 3.98 Mn |
| Mar 31, 2024 | 3.41 Mn |
| Dec 31, 2023 | 6.87 Mn |
| Sep 30, 2023 | 8.84 Mn |
| Jun 30, 2023 | 9.82 Mn |
| Mar 31, 2023 | 8.35 Mn |
| Dec 31, 2022 | 10.26 Mn |
| Sep 30, 2022 | 10.21 Mn |
| Jun 30, 2022 | 8.55 Mn |
| Mar 31, 2022 | 9.03 Mn |